论文部分内容阅读
围生期心肌病是一种特发性、妊娠相关的心肌病,病因还不清楚。其主要特征是既往健康的孕产期妇女,在妊娠晚期至产后5个月期间发生左心室收缩功能减退和心力衰竭。当妊娠晚期或产后早期出现心力衰竭体征时,要高度怀疑围生期心肌病,并早期开始防治。孕妇应避免使用血管紧张素转换酶抑制剂、血管紧张素受体拮抗剂及华法林,因为这些药有可能致畸。一旦分娩,就应该进行标准的心力衰竭治疗。患过围生期心肌病的妇女再次妊娠复发本病的风险很高。该病因与妊娠相关,在诊断和治疗上具有一定的特殊性,近来有不少小规模的前瞻性研究认为溴隐亭治疗围生期心肌病有良好的疗效。现着重针对围生期心肌病的诊断、药物治疗的最新进展进行综述。
Perinatal cardiomyopathy is an idiopathic, pregnancy-related cardiomyopathy, the cause is not clear. Its main feature is the previous healthy pregnant women, left ventricular systolic dysfunction and heart failure occurred during the third trimester of pregnancy to 5 months after delivery. When late pregnancy or postpartum early signs of heart failure, we must highly suspect perinatal cardiomyopathy, and early control. Pregnant women should avoid angiotensin converting enzyme inhibitors, angiotensin receptor blockers and warfarin, because these drugs may be teratogenic. Once delivered, standard heart failure treatment should be performed. Women with perinatal cardiomyopathy have a high risk of relapse after this pregnancy. The etiology and pregnancy related, in the diagnosis and treatment have certain particularity, recently there are many small prospective studies believe that bromocriptine pericardial cardiomyopathy has a good effect. Are focused on the diagnosis of perinatal cardiomyopathy, the latest progress of drug treatment are reviewed.